Auxilium Pharmaceuticals — Q1 2011 Earnings Presentation
31 slides from Auxilium Pharmaceuticals's earnings presentation, May 11, 2011
Slide 1: May 2011
May 2011 (NASDAQ: AUXL) Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks relating to our current plans, potential future events, and what we believe to be the prospects for the Company during this conference call that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Secur
Slide 3: Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company
Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company Maximize Value of Testim and XIAFLEX Deliver on Current Pipeline Build Out Pipeline in Specialty Therapeutic Areas
Slide 4: XIAFLEX and Testim Are Global Product Opportunities
XIAFLEX and Testim Are Global Product Opportunities U.S. Canada EU Japan Open ROW Open Open Territory XIAFLEX Testim
Slide 5: Auxilium Has a Year Net Revenue CAGR of 39.4%
Auxilium Has a 6 Year Net Revenue CAGR of 39.4% 1Q11 XIAFLEX Net Revenues $12.3M (including $10.5M in U.S. revenues) 1Q11 Testim Net Revenues $46.1M, 4% y/y growth
Slide 6: Slide 6
Slide 7: Dupuytren's Contracture Is Debilitating for Patients and Surgery Has Been the Standard of Care
Dupuytren’s Contracture Is Debilitating for Patients and Surgery Has Been the Standard of Care • Excessive collagen in fascia of hand • Nodules or pits are an early, active presentation • Rope-like cords develop in the finger and result in contractures • Quality of life and daily activities affected
Slide 8: We Believe XIAFLEX Is a Paradigm Changing Treatment
We Believe XIAFLEX Is a Paradigm Changing Treatment • Simple, non-invasive injection of XIAFLEX • Established mechanism of action and selective for specific types of collagen • XIAFLEX’s post-approval profile is consistent with clinical trial experience Pre XIAFLEX injection 30 days following XIAFLE
Slide 9: Strategies for Establishing XIAFLEX as the Standard of Care
Strategies for Establishing XIAFLEX as the Standard of Care • Disseminate our excellent clinical efficacy and safety data; • Facilitate peer to peer dialogue with physicians and reimbursement specialists; • Educate patients and health care providers who inject, as well as those who refer to our targ
Slide 10: XIAFLEX Launch Strategy is Tailored to Customer Needs
XIAFLEX Launch Strategy is Tailored to Customer Needs • ~ 6,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists • ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists • Medical science liaisons – Key opini
Slide 11: We Believe the U.S. Dupuytren's Opportunity Is Significant
We Believe the U.S. Dupuytren’s Opportunity Is Significant 70,000 Surgical 2,3,4 Patients Annually 300,000 Diagnosed Patients Annually 2,3,4 >1 Million Diagnosed Patients 2,4 1. Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2. SDI Claims Data Based Projections 3. Medicare Data B
Slide 12: Launch Update Through April 2011
Launch Update Through April 2011
Slide 13: Leading Indicators Trending Positively - Cumulative enrollment & sites that have ordered XIAFLEX
Leading Indicators Trending Positively - Cumulative enrollment & sites that have ordered XIAFLEX
Slide 14: Sites Moving from Test Drive to Increasing Usage
Sites Moving from Test Drive to Increasing Usage Injections per Site
Slide 15: Quarterly XIAFLEX Revenue (in $ millions)
Quarterly XIAFLEX Revenue (in $ millions) * Includes one-time revenue recognition change of $1.8 million *
Slide 16: We Expect the Global Dupuytren's Market to Develop in 2011 and 2012
We Expect the Global Dupuytren’s Market to Develop in 2011 and 2012 U.S. • XIAFLEX specific J-code J0775 effective Jan. 1 • U.S. CPT code guidance expected for Jan. 2012 • Additional phase IV clinical trials • Increasing peer to peer dialogue programs for U.S. physicians • Targeted U.S. patient educ
Slide 17: Testim 1% Testosterone Gel
Testim ® 1% Testosterone Gel • Indicated for testosterone replacement therapy in adult males for hypogonadism • Launched in U.S. in 2003 and EU in 2006 • >7 yrs of use with established safety and efficacy > ~100M daily doses since launch > 16 clinical studies involving approx. 1,800 patients • Appli
Slide 18: Hypogonadism Is an Unmet Need and Under-penetrated Market
Hypogonadism Is an Unmet Need and Under-penetrated Market • 39% of U.S. males over 45 yrs are hypogonadal > Less than 10% of affected population receives treatment • Increasing physician and patient education and awareness should result in increased treatment Mulligan T. et al. Int J. Clin Pract
Slide 19: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data $35 $117 $198 $281 $334 $371 $439 $545 $685 $892 $1,149 $49 $59 $77 $118 $210 $302 $390 $451 $483 $554 $663 $810 $1,041 1,000 1,200 1,400 Gel Patch Oral Injectables ($ in millions) Gel Segment Growth ($) Mar 2011 L12M: 27.
Slide 20: Testosterone Replacement Therapy Landscape is Changing
Testosterone Replacement Therapy Landscape is Changing • New competition in 2011 should help increase overall market – Axiron 2% solution – Fortesta 2% gel – Androgel 1.6% gel • Expected further increase in physician and patient education and awareness
Slide 21: Delivering on Current Pipeline
Delivering on Current Pipeline TESTIM® GEL XIAFLEX® XIAFLEX® XIAFLEX® PRODUCT LATE RESEARCH PRE-CLINICAL PHASE I PHASE II PHASE III MARKET Hypogonadism Dupuytren’s contracture Peyronie’s disease Frozen Shoulder Syndrome
Slide 22: Peyronie's disease Is a Devastating Disorder with No Approved Therapies
Peyronie’s disease Is a Devastating Disorder with No Approved Therapies Smith BH. Am J Clin Pathol . 1966;45:670-678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with er
Slide 23: We believe Peyronie's Disease Is Under-diagnosed and Under-treated
We believe Peyronie’s Disease Is Under- diagnosed and Under-treated Bella A. Peyronie’s Disease J Sex Med 2007;4:1527–1538 Lue TF, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6–23. Mulhall JP, et al. Subjective and objective analysis of the prevalence of Pey
Slide 24: Peyronie's Disease Phase III Development Program
Peyronie’s Disease Phase III Development Program Study Type ~ # Subjects Sites XIAFLEX: Placebo Duration AUX-CC-803 Double-blind, placebo controlled ~ 30 US 5 AUS 2:1 52 Wks AUX-CC-804 Double-blind, placebo controlled ~ 30 US 5 AUS 2:1 52 Wks AUX-CC-802 Open Label 12 US 6 NZ 18 EU N/A 36 Wks AUX-CC-
Slide 25: We Believe Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III
We Believe Changes to the Phase IIb Trial Design Should Increase the Chance of Success in Phase III • 4 cycles of therapy in the phase III trial • All patients receive modeling in the phase III trial • All patients must have greater than 12 months of disease since diagnosis to enter the phase III tr
Slide 26: Business Development Efforts Expected to Focus on Building Out Pipeline
Business Development Efforts Expected to Focus on Building Out Pipeline • Leverage current infrastructure of Testim and XIAFLEX field forces with marketed products • Seeking Phase II and later assets in Urology, Endocrinology, Rheumatology, and Orthopedics • Niche products with specialty physician c
Slide 27: BTC Litigation Update
BTC Litigation Update • On Feb. 15, 2011, AUXL filed a complaint against BioSpecifics Technologies Corp. (BTC) alleging that BTC has breached the parties’ Amended and Restated Development and License Agreement dated as of December 11, 2008 by its commencement of clinical trials for the use of inject
Slide 28: 1Q 2011 Financial Results ($ Millions)
1Q 2011 Financial Results ($ Millions) (Decr.) 1Q11 1Q10 $ % Total Revenues $58.4 $45.5 $12.9 28% Cost of Goods Sold * $11.3 $9.5 $1.8 19% Gross Profit $47.1 $36.0 $11.1 31% % of Revenues 81% 79% R & D Expense * $15.8 $8.5 $7.3 86% SG&A Expense * $43.2 $36.1 $7.1 20% Net Loss ($11.8) ($8.6) ($3.2) (
Slide 29: 2011 Guidance
2011 Guidance Global Testim Revenues $200 - 210 million Xiaflex: US Revenues 50 - 60 million Ex US / Def Rev 9 - 11 million Total Xiaflex $59 - 71 million Total Revenues $259 - 287 million R & D Expense $60 - 70 million S G & A Expense $170 - 180 million Net Income (Loss) $(31) - (41) million Stock
Slide 30: We Believe That Auxilium is Well-Positioned for Long-Term Growth
We Believe That Auxilium is Well-Positioned for Long-Term Growth • Maximize XIAFLEX net revenues for Dupuytren’s contracture in the U.S.; • Maximize global Testim revenues. • Support Pfizer in the launch of XIAPEX for Dupuytren’s contracture in the EU; • Complete Peyronie’s disease phase III double-
Slide 31: Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company
Our Vision Is to Become a Rapidly Growing, Profitable and Sustainable Biopharmaceutical Company Maximize Value of Testim and XIAFLEX Deliver on Current Pipeline Build Out Pipeline in Specialty Therapeutic Areas
Auxilium Pharmaceuticals — Q1 2011 Earnings Presentation on 6ix